Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis

Table 3 Meta-analysis of relationships between mTOR/p-mTOR expression and clinicopathological characteristics of ESCC

Clinicopathological characteristics	N	No. samples			Heterogeneity (I², p)	Model	OR with 95 % CI	P value	Publication bias		Conclusion
Clinicopathological characteristics	N	Total	PE	NE	Heterogeneity (I², p)	Model	OR with 95 % CI	P value	Begg (p)	Egger (p)	Conclusion
Differentiation (G3 vs G1/G2)	6	568	285	283	I² = 29.3 %, p = 0.216	Fixed	2.634 (1.714–4.047)	0.001	0.283	0.456	Significant
Depth of tumor invasion (T3/T4 vs T1/T2)	6	568	318	250	I² = 0.0 %, p = 0.546	Fixed	1.477 (1.024–2.132)	0.037	0.452	0.355	Significant
TNM stage (III/IV vs I/II)	7	776	385	391	I² = 82.9 %, p < 0.001	Random	2.248 (1.048–4.823)	0.037	0.087	0.216	Significant
Lymph node metastasis (Yes vs No)	8	838	418	420	I² = 69.2 %, p = 0.002	Random	1.816 (1.062–3.105)	0.029	0.754	0.626	Significant
Gender (Male vs Female)	6	741	363	378	I² = 0.0 %, p = 0.447	Fixed	0.811 (0.500–1.316)	0.396	0.371	0.273	Not significant

CI confidence interval, ESCC esophageal squamous cell carcinoma, mTOR Mammalian Target of Rapamycin, N reference count, NE negative expression, OR odds ratio, PE positive expression, p-mTOR Phosphorylated Mammalian Target of Rapamycin

ISSN: 1471-2407